Atlas Trials

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Clinical trial NCT05325684 · UNKNOWN

Trial details

NCT number
NCT05325684
Sponsor
The Affiliated Hospital of Qingdao University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
EfficacySafety
Start date
2022-04-01
Primary completion
2023-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.